NEO
NeoGenomics, Inc.
Diagnostics & Research · Healthcare · United States
16.39
close · 2026-08-13
value
37
cheaper than peers37
quality
33
stronger fundamentals33
ranked against
Diagnostics & Research
value
quality
28 peers
Value inputs
| measure | company | vs peers |
| price to book | 2.67× | 75 |
| price to sales | 2.66× | 72 |
| forward P/E | 48.47× | 13 |
| EV to EBITDA | 97.57× | 9 |
4 of 12 measures available
Quality inputs
| measure | company | vs peers |
| revenue growth | 11.2% | 52 |
| debt to equity | 57.1% | 48 |
| return on equity | -6.3% | 37 |
| operating margin | -4.8% | 35 |
4 of 4 measures available
Facts
| market cap | $2B |
| free cash flow | $48.2M |
| employees | 2,500 |
| first trade | 2004-03-16 |
| next earnings | 2026-07-28 |
| fundamentals updated | 2026-07-30 |